INFORMATION DISCLOSURES ATTY. DOCKET NO.	SERIAL NO.	
CITATION 604-781	10/584,470	
MAR 17 2009 CHIBBER		
(Use several sheets if necessary)	GROUP	
(Use several sheets if necessary) June 22, 2006	1623	

		L L	I.S. PATENT DOCUMENTS			
EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
INITIAL I	6,787,151	DATE 09/2004	Meijer et al	CLASS	JOBOLAGO	
	5,104,856	04/1992	Esko et al			
	5,360,733	11/1994	Fukuda et al			
	5,461,143	10/1995	Wong et al			
		01/1996	Bouic et al		<u> </u>	
	5,486,510		Tashiro et al			
	5,589,182	12/1996				
	5,624,832	04/1997	Fukuda et al		<u> </u>	
	5,658,778	08/1997	Fukuda et al			
	5,843,707	12/1998	Larsen et al			
	5,880,091	03/1999	Cummings et al			
	5,886,029	03/1999	Dhaliwal		ļ	
	5,952,393	09/1999	Sorkin, Jr.			
	5,958,770	09/1999	Cham et al			
	5,965,449	10/1999	Novak			
	5,985,936	11/1999	Novak		<u> </u>	
	6,042,834	03/2000	Baraka			
	6,087,353	07/2000	Stewart et al			
	6,197,832	03/2001	Sorkin, Jr.			
	6,346,267	02/2002	Fry et al			
	6,383,514	05/2002	Weitkemper et al			
	6,407,085	06/2002	Kief			
	6,635,461	10/2003	Schwientek et al			
	6,933,291	08/2005	Qi et al			·
	6,998,501	02/2006	Wright et al			
	2004/0038923	02/2004	Marth et al			
	2004/0203111	10/2004	Schwientek et al		<u> </u>	
	2002/0018811	02/2002	Penteado et al			
	2002/0098563	07/2002	Korczak et al			
	2002/0156051	10/2002	Kutney et al			· · · · · ·
	2003/0096316	05/2003	Wester			
	2004/0033521	02/2004	Korczak et al		 	
	2004/0049352	03/2004	Andre et al			
			Cham		 	
	2004/0220115	03/2006	Platt et al		1	
	2006/0052351	11/2007	Liu et al			
	2007/0254847					
	2002/0183294	12/2002	Barraclough et al			
	2002/0193317	12/2002	Xia et al			
	2003/0004147	01/2003	Barraclough et al			
	2004/0249138	12/2004	Lawson		ļ	
1	2007/0254847	11/2007	Liu et al			<u> </u>

						
1	1					
	D. 4. O					
*Examiner	Date Considered					
Examiner: Initial if reference considered, v	hether or not citation is in conformance with MPEP 609; draw line through citation if not i	n conformance and not considered. Initial a				
this form with next communication to applicant.						

Sheet 2 of 4

*Examiner

INFORMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.	
CITATION	604-781	10/584,470	
	APPLICANT		
	CHIBBER		
(Use several sheets if necessary)	FILING DATE	TC/A.U.	
	June 22, 2006	1623	

			REIGN PATENT DOCUMENTS			TRANSI	ATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	2 335 436	08/2001	Canada				
	1237583A	12/1999	China	_		ABSTR	X
	1243129A	02/2000	China			ABSTR	X
	1361111A	07/2002	China			ABSTR	X
	0 850 243 B1	10/2003	EP				
	1 316 608 A1	06/2003	EP				
	2 027 434 C1	01/1995	RU			х	
	WO 00/52029 A1	09/2000	PCT				
	WO 00/78789 A1	12/2000	PCT				
*	WO 02/87548	11/2001	PCT				
	WO 02/24212 A1	03/2002	PCT				
	WO 01/83717 A2	11/2001	PCT				
	WO 02/069980 A2	09/2002	PCT				
	WO 03/075931 A1	09/2003	PCT				
	WO 2004/002497 A1	01/2004	PCT				
	WO 2004/111196 A2	12/2004	PCT				
	WO 2004/029068 A1	04/2004	PCT				
	WO 2004/048938 A2	06/2004	PCT		1		
	WO 98/06405 A1	02/1998	PCT				
	WO 99/39715 A1	08/1999	PCT		1		
	WO 99/53925 A1	10/1999	PCT				
	WO 97/06176 A2	02/1997	PCT				
	OTHER DOCK	JMENTS (ir	ncluding Author, Title, Date, Pertinent p	oages, e	tc.)		
			ures of furostanol saponins (48 pgs).				
	Battistini, L. et al; "CD	3 ⁺ T cells fro	m patients with acute multiple sclerosis displa	y selecti	ve increase of	f adhesive	eness i
	brain venules: a critical	role for P-se	lectin glycoprotein ligand-1", Blood, Vol. 101	No. 12,	4775-4780 (2	003).	
	Ben-Mahmud Bahaedi	n M., et al: '	"Tumor Necrosis Factor-α in Diabetic Plasma	Increases	the Activity	of Core	2
			n Leukocytes to Retinal Endothelial Cells"; D				
	Brockhausen, I., et al:	Biosynthesi	s of O-Glycans in Leukocytes from Normal D	onors and	d from Patien	ts with	
			re 2 UDP-GlcNAc:Galβ1-3GalNAc-R (G1cN				
			ukemic Cells"; Cancer Research; 51, 1257-12				
	Buerke, Michael, et al;	'Sialyl Lewi	sx- Containing Oligosaccharide Attenuates M	yocardial	Reperfusion	Injury in	Cats"
	J. Clin. Invest.; Vol. 93,	1140-1148 (1994).		_		
	Beum, P.V. and Cheng,	Pi-W.; " <i>B</i> ios	synthesis and Function of β1,6 Branched Muc	in-Type (Glycans"; The	Molecul	lar
	Immunology of Complex			7.1	•		
			sis: upregulation of core 2 β1,6 N-acetylgluce				

 Th2 cytokines in a human airway	epithelial cell line"; Am J. Physiol I	Lung Cell Mol Physiol.; 2	288: L116-L124 (2005).
•	•		

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

of

INFOR	MATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.	_
	CITATION	604-781	10/584,470	
		APPLICANT		_
		CHIBBER		
(Us	e several sheets if necessary)	FILING DATE	TC/A.U.	-
,				
		June 22, 2006	1623	_
	Paum D.V. at al. 'Myoin	Diographagia Enidormal Grayth L	actor Downregulates Core 2 Enzymes in a Human Airway	_
		e"; Am. J. Respir. Cell Mol. Biol.;		′
			Heparan Sulfates Attached to Collagen Type XVIII"; J. Bi	\overline{ol}
	Chem.; 280(29); 26965-73	; Epub (2005).	·	
			folecules Icam-1, Vcam-1, Pecam, and E-Selectin in Hum	an
		of Pathology, Vol. 171: 223-239 (1		
	Glycobiology; Vol. 3, No.		Fransferase and polylactosamine expression in O-glycans"	,
			n - Potential for Therapeutics and Diagnostics", Nature	
	Reviews, Vol. 4, No. 6, 47			
			Nm23-H1 on Glycosy-transferases Involved in the	
		Antigens"; J. Cell. Biochem.; 94:12		
		Cell Surface Antigen (1305) Founs"; J. Immunol. Vol. 131, No. 2, 70	d in Increased Fequency on Acute Leukemia Cells and in	
			or Family Recognize a Common Carbohydrate Epitope, the	 ie
		ride"; J. Cell Biol.; Vol. 117, 895-9		
	Fugang P. et al.; "Post Tr	anslational Modifications of Recor	nbinant P-selectin Glycoprotein Ligand-1 Required for	
		n"; J. Biol. Chem.; Vol. 271, No. 6		
			ressing mice is associated with decreased VEGF gene	
	Goss P. F. et al: "Inhibito	ysiol; Vol. 93, 2162-2170 (2002).	New Class of Anticancer Agents ^{1,2,} ; Clin. Cancer Res.; Vo	<u></u>
	1, 935-944 (1995).	is of Caroonyurate Processing. A	tew class of Anticancer Agents , Clut. Cancer Res., Vi	<i>J</i> 1.
		Synthesis of a divalent sialyl Lewis	x O-glycan, a potent inhibitor of lymphocyte-endothelium	n
	adhesion"; Eur J. Biochem			
			ninyltransferase and High Endothelial Venule-restricted	
			g"; J. Biol Chem.; Vol. 279, No. 4, 3058-3067 (2004). NSC-698793) and Gracillin (NSC-698787), Two Steroids	-1
		• •	glauca, against Human Cancer Cells in vitro"; Phytother.	11
	Res.; 17; 620-626 (2003).		,,,,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,	
	Kumar, A. et al; "Recomb	inant Soluble Form of PSGL-1 Ac	celerates Thrombolysis and Prevents reocclusion in a	
	Porcine Model"; Circulation	on; 99, 1363-1369 (1999).	·	
			onally synthesized novel core 2-like branched structure	
			e sequences"; Glycobiology, Vol. 8, No. 7; 707-717 (1998)	<u>). </u>
			d Cardiac Dysfunction"; Circ Res.; 96; 925-926 (2005).	<u></u>
	,	in and ethinyl estradiol", Hepatolo	secretion is associated with abcg5 and abcg8 expressions	ın
			olate mofetil and systemic lupus erythematosus"; Lupus,	14.
	17-26 (2005).			
	Martininez, M. et al; "Reg		th L-selectin, P-selectin, and E-selectin"; J. Biol. Chem.,	
	Vol. 280, No. 7, 5378-539			
			setylglucosaminyltransferase Selectively Contributes to P- Journal of Immunology, 174: 4051-4059 (2005).	
			perapeutic Potential of Tunicamycin in Murine L1210	
	Leukemia"; Cancer Res. 4.	•		_
		· · · · · · · · · · · · · · · · · · ·		
xaminer		Date	: Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of 4

et 4 of 4		
INFORMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.
CITATION	604-781	10/584,470
	APPLICANT	
	CHIBBER	
(Use several sheets if necessary)	FILING DATE	TC/A.U.
	June 22, 2006	1623
Sialy-Le ^x Expression Level Chem.; 273, No. 41; 2677	el in Human Pre-B Lymphocytic L 9-26789 (1998).	-6-N-acetylglucosaminyltransferase, Regulates Cell Surface eukemia Cell Line KM3 Treated with Phorbolester"; J. Biol. Glomeruli is Augmented following Diabetes mellitus";
Nephron; 89, 161-171 (20	00).	
Okada, S. et al; "Intercell Diabetes"; Diabetes; 52:25		nt Mice are Resistant Against Renal Injury After Induction of
Piccio L. et al; 'Molecula	ar Mechanisms Involved in Lympho	ocyte Recruitment in Inflamed Brain Microvessels: Critical ric G _i -Linked Receptors ¹ "; <i>J. Immunol.</i> ; 168: 1940–1949
Ravnskov, U.; "Is atheros	clerosis caused by high cholesterol	
Ross, Russell; "Atheroscle 126 (1999).	erosis - An Inflammatory Disease"	, The New England Journal of Medicine, Vol. 340, 2, 115-
I II I	nda A. Cattle; "Sialyl Ligands faci Journal of Neuroimmunology, 41; 1	litate lymphocyte accumulation during inflammation of the 23-130 (1992).
Steinberg, D.; "Atheroger Medicine; Vol. 8, No. 11;	nesis in perspective: Hypercholester 1211-1217 (2002).	rolemia and inflammation as partners in crime"; Nature
Drug Discovery, Vol. 4, 5	10 – 518 (2005).	rapy for Multiple Sclerosis: Natalizumab"; Nature Reviews:
No. 4, 218-222 (1994).		Phospholipase A ₂ by Dioscin"; Arch. Pharm. Res.; Vol. 17,
	eukocyte and endothelial cell adher ends in Pharmacological Sciences	sion molecules as targets for therapeutic interventions in Vol. 24, No. 12; 640-647 (2003).
Gland UDP-G1cNAc:Gal No. 23; 1253-1261 (1980)	31-3GalNAc(GlcNAc — Ga1NAc)	y and Product Identification Studies on Canine Submaxillary β6-N-acetylglucosaminyltransferase"; J. Biol. Chem.; 255,
Biol.; 24, 66-73 (2001).		Cell Metaplasia in Mouse Lung"; Am. J. Respir. Cell Mol.
* Yu, Jing et al, "Progress is	n studies on chemical constituents	and pharmacological effect of Trigonella foenum-graecum",

	1	1
*Examiner	Date Considered	
	•	

Chinese Traditional and Herbal Drugs, Vol. 34, (12) 1146-1149 (2003).

Zak, I., et al; "Selectin Glycoprotein Ligands"; Acta Biochemica Polonica; Vol. 47, No. 2; 393-412 (2000).